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that a positive correlation exists in hospitals between service specialization and 
the level of clinical quality; furthermore, one also exists between clinical quality 
and financial performance. Finally, service specialization has a positive effect on 
financial performance, which is fully mediated by clinical quality. 
CONCLUSIONS: Based on a complete set of national data, this study 
demonstrates that hospital specialization has positive effects. Specialist hospital 
organizations provide superior quality of care and enhanced financial 
performance. Consequently, more specialization may prove to be a beneficial 
policy for the NHS.  
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OBJECTIVES: The European Union (EU) and the United States (US) have different 
regulatory systems for pre-marketing approval of medical devices (MDs) that 
result in differences in the MDs market authorizations and dates of market 
entry. This study analyzed differences between the MD regulatory systems in the 
US and the EU and evaluated the effect of those differences in pre-marketing 
authorization of new MDs in the period January 2000 to September 2012. 
METHODS: The study included a comparison of the regulation of MDs in the EU 
and the US and an analysis of MDs pre-marketing authorization dates in both 
systems in the period January 2000 to October 2012. Data were collected from the 
US Food and Drug Administration (FDA), companies’ webpages and a review of 
the literature. Descriptive statistics were used to compare differences in 
approval dates. Regression analysis was used to assess trends in differences in 
approval dates over the study period. RESULTS: There were important 
differences in pre-marketing approval systems for MDs between the US and the 
EU. More clinical information was required for approval of MDs in the US than in 
the EU. The FDA listed 514 new MDs approved in the study period. FDA pre-
marketing authorization and EU pre-marking authorization (i.e. CE mark) dates 
were available for 201 MDs. Approval of MDs occurred on average±stdev 
2.57±3.79 years earlier in the EU than in the US (median=2.42 years; 95%CI=1.86-
3.29 years). Overall, 171 MDs (85.1%) were authorized first in the EU. The 
difference in authorization dates grew over the study period at a rate of 
approximately 2.5 months per year. CONCLUSIONS: The EU and the US have 
different safety and efficacy regulatory requirements for MDs pre-marketing 
authorization. European patients have early access to new devices, whereas US 
patients have more MD-related information available for reimbursement and 
clinical decisions.  
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OBJECTIVES: The Commonwealth of Massachusetts implemented the first phase 
of a broad health care reform program from 2006 through 2008. The 
Massachusetts (MA) reform has increased insurance coverage and improved 
access to care. How the ACA will affect the hospital sector is undefined. The 
objectives of this study were to examine the effects of health care reform on 
inpatient services and emergency department visits in MA. METHODS: We used 
data from AHRQ's Healthcare Cost and Utilization Project (HCUP) State Inpatient 
Databases (SID) and the State Emergency Department Databases (SEDD). We 
implemented a difference-in-difference model to estimate the impact of the 
legislation and examined the changes between 2005 and 2009 in both MA and in 
control hospitals for a limited number of high-level indicators: discharges 
(overall and in selected categories); length of stay; cost per discharge; and 
emergency department (ED) visits and charges. We also estimated regression 
models that controlled for the hospital’s competitive environment for both the 
inpatient and ED variables. There were 64 MA hospitals with nonmissing values 
for all of the variables used in this study (62 with EDs). The control populations 
were propensity-score matched samples of hospitals drawn separately from the 
SID and the SEDD. RESULTS: Changes in inpatient utilization in MA were similar 
to those in other states. Length of stay declined more rapidly relative to the 
control sample (–6.0% versus –0.4%, respectively. The number of preventable 
hospitalizations for acute conditions declined in MA and the rest of the country. 
Hospitalizations associated with chronic conditions increased overall; results are 
at least suggestive that they rose faster in MA (0.05<p< 0.10). ED utilization grew 
in both groups, but ED charges per visit grew more slowly over the 5-year period 
in MA. CONCLUSIONS: Overall, the Massachusetts reform had modest effects on 
the hospital sector.  
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OBJECTIVES: Health insurance exchanges (HIX) are regulated, standardized 
online marketplaces that allow consumers to compare and purchase health 
insurance coverage. The U.S. Patient Protection and Affordable Care Act (2010) 
required all states and the District of Columbia to choose between establishing 
state-controlled HIX, either independently or through a state-federal 
partnership, or else defer to federally-controlled programs. Following a 
December 2012 decision deadline, 18 states and the District of Columbia opted to 
establish state-based programs, 7 states opted for partnership programs, and 25 
states defaulted to federally-controlled programs. The objective of this study was 
to examine variables associated with the adoption of federally-controlled HIX 
versus state-controlled and partnership HIX. METHODS: This descriptive, cross-
sectional study used publically available state-level data (n=51) from 2009 to 
2012. Information was obtained from sources such as the Kaiser Family 
Foundation and the Centers for Medicare and Medicaid Services. Chi-square 
analyses were performed on categorical variables in relation to federal versus 
state-controlled and partnership HIX and t-tests were used to compare means of 
continuous variables. RESULTS: 19 continuous and 5 categorical variables, 
including political, economic, and population health measures, were included in 
this analysis. Of these, political party of the governorship (p<0.001), 2012 
Electoral College result (p<0.01), decision regarding Medicaid expansion 
(p<0.001), unemployment rate (6.78% for federally-controlled HIX vs. 7.79% for 
state, p<0.05), and Medicaid enrollment in the <200% of Federal Poverty 
Guideline population (37.1% for federally-controlled HIX vs. 44.5% for state, 
p<0.05) were found to be significantly associated with default to federally-
controlled HIX. CONCLUSIONS: States that opted for, or defaulted to, federally-
controlled programs have shared political, economic, and population 
characteristics that may impact HIX design, implementation, and 
administration. Access to other state-level data may yield further significant 
findings.  
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OBJECTIVES: In France assessments by the Transparency Committee (TC) plays a 
significant role in pricing and market access of new products. TC evaluates 
clinical efficacy and safety data of new interventions, and compares it to current 
standard of care. TC’s assessments are made using ASMR ratings ranging from I 
to V (major innovation to no improvement). The objective of this study was to 
understand trends in TC’s assessments for new products approved by the EMA 
between 2011-2012. METHODS: TC’s assessments for 11 products approved by 
the EMA between 2011-2012 were analyzed for their ASMR ratings. Analysis was 
conducted to identify new trends and compare them for products based on their 
indications, comparators, and launch timing. RESULTS: Analysis of 2011-2012 
assessments by TC shows that the majority of products (73%) received an ASMR 
rating of IV (minor improvement). Approximately 27% of the products received 
an ASMR rating of III and V. A new trend in TC’s assessment is the assignment of 
two ASMR ratings for one product for different subgroups or patient line of 
treatment. During last one year 3 out of 11 products received two ASMR ratings. 
None of the products received ASMR ratings of I and II. The products that 
received ASMR rating of V (no improvement) were indicated for cardiovascular, 
epilepsy, and bone metastases. All assessments included analysis of 
intervention’s data versus one or more comparators. CONCLUSIONS: France TC’s 
assessments trends show a need for robust comparative effectiveness data to 
obtain better ASMR ratings, which affects both pricing and market access of new 
products. Future products would need subgroup analysis to obtain high ASMR 
ratings for all patient populations.  
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OBJECTIVES: In the pursuit of performance enhancement in the health care 
system in Egypt, particularly in the pharmaceutical sector, researchers face 
severe lack of relevant data. This limits our understanding of the health care 
system and the ability to detect policy-relevant problems. This is especially true 
for community pharmacies, which make the most easily accessible health care 
avenues for Egyptian households. We, therefore, sought to explore the 
characteristics of Egyptian community pharmacies in terms of labor force and 
practice patterns. METHODS: This is the first wave of a modified cross-sectional 
survey adapted from the US National Pharmacist Workforce Survey.  
We randomly sampled pharmacies located in the East and South regions of Cairo 
from addresses listed in Yellow Pages using a systematic random sampling 
methodology. Pharmacy data was collected through personal interviewing of the 
pharmacist on duty in the surveyed pharmacies. RESULTS: One-hundred- 
and-sixty-nine pharmacies participated in the survey (72% response rate). 
Independent pharmacies accounted for 88% of respondents. Only 35% of  
the pharmacies had a full time pharmacist, while 20% suffered recent layoffs  
of pharmacists. Virtually all pharmacies offered disease and medication 
counseling, 58% offered compounding services, 56% offered drug information 
services, and 40% carried durable medical equipments. Respondent pharmacists 
were on average 31.6 years old; 62% were male; the majority (94%) had only  
the bachelor's of pharmacy degree; work 56.3 hours per week; and receive  
6.05 Egyptian Pounds (EGP) (~ $1) per hour in compensation. Males reported 
working more weekly hours (58.8 vs. 52.4, p=0.02) but the average hourly  
rate was not statistically different from females (6.12 vs. 5.94 EGP, p=0.2). 
CONCLUSIONS: This study illustrates an ongoing effort to document  
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the characteristics of community pharmacies in Egypt. The current study and 
future ones would significantly improve the ability to probe practice-related 
issues and economic challenges community pharmacies and pharmacists face in 
Egypt.  
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OBJECTIVES: HTA agencies are mushrooming in Europe. Industry faces the 
challenge to meet their diverse requirements and comply with decision criteria. 
Our aim was to investigate similarities and distinguishing characteristics of HTA 
agencies, to identify the anchor institutes that use different approaches to HTA 
and serve as a reference for others, and to assign other countries to one of the 
anchor institutes. METHODS: We identified the primary institutions in European 
countries where HTA plays a role in decision making. We developed a template 
for the unified assessment of the input needs of the agencies, and a set of 
criteria an anchor country should meet.. Agencies were assessed based on a 
literature review, and assigned to one of the anchor countries, which was 
validated by MSD subsidiaries across Europe. Future trends in anchor countries 
were investigated. RESULTS: We identified three anchor institutes in Europe 
using different value assessment concepts. IQWIG in Germany primarily 
assesses HTA submissions on the basis of patient related outcomes requiring 
hard endpoints. HAS in France sees the medical benefit of technologies in 
innovativeness rating them from no innovation to breakthrough innovation. 
NICE in England asks for evidence of cost-effectiveness as one of its major 
considerations. We found that other European countries tend to primarily follow 
one of these concepts. Analysing future trends, one can see converges in the 
fields of HTA requirements, between regulatory and HTA, in coordination and 
process harmonization, and regional and international collaboration. 
CONCLUSIONS: European HTA agencies can be systemized based on their 
requirements. This review can serve as a depository of individual country needs 
in HTA, an input to the design of clinical trials, and can support the development 
of industrial HTA strategies. Such a snapshot however cannot substitute the 
deep knowledge of local requirements and needs regular update to follow-up 
future trends.  
 
PHP142  
CHANGES IN THE NUMBER OF ENROLEES IN THE HUNGARIAN MANAGED CARE 
PROGRAMME  
Boncz I, Ágoston I, Vajda R, Jankó-Király A, Lampek K 
University of Pécs, Pécs, Hungary  
OBJECTIVES: A pilot care managing programme was introduced in Hungary in 
1999. The conceptual foundations of the Hungarian implementation of managed 
care is closer to what was called the GP fundholding in the UK than HMOs in the 
USA. The purpose of the study is to analyse the changes in the number of 
enrolees in the care managing programme. METHODS: The data derive from the 
financial database of the Hungarian National Health Insurance Fund 
Administration (NHIFA) covering the period 1999-2007. We identified the average 
annual number of persons enrolled to Care Managing Organizations. The 
Hungarian CMOs was financed through a risk adjusted capitation fee and the 
health services covered by CMOs were defined in legal regulations. RESULTS: 
The total number of the Hungarian population was around 10 million people  
(100 %) during the study period. Since the beginning of the programme (1999) the 
total number of persons covered by the care managing programme increased 
from 158,984 (1.5 % of the Hungarian population) to 601,915 persons (5.9 %)  
in 2003 and to 1,961,025 (19.4 %) in 2005. After this peak, the number of enrolees 
decreased to 1,823,732 persons in 2006 and 1,409,475 persons in 2007. Later  
the Hungarian managed care pilot programme was cancelled. CONCLUSIONS: 
With the development of the Hungarian care managing system, the  
average number of enrolees increased. This increase resulted in larger risk-
pooling structure providing a more stable environment for Care Managing 
Organizations.  
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OBJECTIVES: To determine the types of approaches preferred by payers to 
enhance the P&T decision-making process and how medications accepted onto 
the formulary should be covered. METHODS: An online-interactive survey of US 
medical/pharmacy directors (MDs+PDs, respectively). In addition to a 10-point 
Likert scale (10=agree completely, 1=disagree completely), some questions used 
qualitative responses and interpretive analysis to explore views and beliefs. 
RESULTS: Twenty-nine (20 MDs+9 PDs) responded, representing 44 commercial 
plans,19 Medicaid plans, and 23 Medicare plans. Respondents indicated that 
current progress in obtaining usable comparative-effectiveness research (CER) 
information was slow (average=4.17; MD=4.06; PD=4.40 on the 10-point scale). 
However, they anticipate regularly utilizing CER information in formulary 
decision making by 2015 (average=6.03; MD=6.0, PD=6.1). Their rating of the use 
of evidence-based medicine in coverage decision making today was somewhat 
higher (average, 7.08; MD=7.38, PD=6.40). The survey participants pointed out 
that emerging CER results will greatly affect the following areas: 
Optimization/improvement of clinical guidelines (22.6%), medical/pharmacy 
benefit management (19.4%), evaluation of the value (16.1%), appropriateness of 
care (16.1%), pharmaceutical R&D (6.5%). When asked how they would change 
their plan/PBM’s pharmacy benefit design, the most frequent responses  
were incorporating CER data into copayment tiering management (13.3%), 
further incentivizing adherence through benefit design (10.0%), and altering 
benefit design structures for specialty pharmaceuticals (10.0%), primarily 
lowering member out-of-pocket costs. To improve their P&T Committee process, 
23.3% would incorporate more CER results, 13.3% would enhance the 
physician/specialist presence on the review committee, and 6.6% would increase 
the time allowed for review to allow for a more in-depth evaluation. 
CONCLUSIONS: The environment for P&T Committee decision making  
in managed care is undergoing a series of changes, and payer medical directors 
and pharmacy directors, who commonly serve as P&T Committee  
members, have distinct opinions as to how to alter the process to adapt to these 
influences.  
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OBJECTIVES: Patient Access Schemes (PASs) are part of the UK Pharmaceutical 
Price Regulation Scheme (2009). PASs enable patients to receive drugs, and allow 
pharmaceutical companies to collect cost-effectiveness and efficacy data, even if 
the payer classified the drug as outside the cost-effectiveness threshold. This 
project analysed the effect of PASs on patient access (PA) (defined by total sales 
in volume/prevalence of the particular disease group). METHODS: A literature 
search of Medline and online resources was carried out to capture relevant data 
on PASs, however no suitable publications on the relationship between PA and 
PASs were obtained. Multiple regression was used to test if a relationship exists 
between the dependent variable, (change in PA) and the independent variable 
(existence of a PAS) and other factors that may affect change in PA. The other 
factors were: type of PAS, country, number of competitors, list price, how long 
the drug has been marketed for, and the orphan drug designation. Five drugs 
with approved PASs in the UK were analysed. These included: lenalidomide, 
erlotinib, bortezomib, sunitinib, and cetuximab. These were analysed in France, 
Germany, Italy, Spain and the UK, between 2010 and 2011 using IMS sales data 
and the Globocan Project 2008 prevalence data. RESULTS: The results of the 
regression analysis showed the existence of a PAS does not seem to have an 
effect on the change in PA. Therefore, this model cannot support a relationship 
between these two variables. The R2 is 0.6119, however the only variable which 
was statistically different from 0 is the number of competitors, with a p-value of 
0.014; which means it is the only variable which had a significant effect on the 
change in PA. CONCLUSIONS: Further research needs to be conducted for a 
detailed analysis on this relationship.  
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OBJECTIVES: The Centers for Medicare and Medicaid Services (CMS) makes 10-12 
National Coverage Determinations (NCDs) for medical interventions each year. 
Our objective was to identify evolving trends in NCDs. METHODS: We analyzed 
data from the Tufts Medical Center NCD database, which contains detailed 
information on 165 NCDs since 1999. We evaluated trends in how CMS reported 
evidence limitations, the use of its “coverage with evidence development” (CED) 
policy, the type of intervention evaluated, and whether it was for prevention or 
treatment. We used two-sided Armitage-Cochrane (CA) tests to identify 
statistical annual trends. RESULTS: Over time, CMS has increasingly cited 
evidence limitations in decision memoranda. The proportion of occasions CMS 
cited a “lack of relevant health outcomes” increased from 14% in 2000 to 67% in 2012 
(p<0.0001; CA test, 1999-2012). The proportion of occasions CMS cited, a “lack of 
studies including Medicare beneficiaries” increased from 7% in 2000 to 67% in 2012 
(p=0.0003; 1999-2012). CMS has increasingly relied on coverage with evidence 
development (CED) policies (p=0.0292; 2003-2012). Since 2009, 10 NCDs (29% of 
NCDs in this period) resulted in CED policies, more than half of all CEDs (n=19) 
implemented since 2003. In recent years, NCDs have increasingly pertained to 
primary and secondary prevention level interventions (p=0.0971; 1999-2012), and 
now represent 28% (46/165) of all NCDs. The type of intervention evaluated also 
changed, with more NCDs pertaining to “diagnostic imaging technology” 
(p=0.0971; 1999-2012), now representing 15% (25/165) of all NCDs, and “health 
education and behavior” (p=0.0195; 1999-2012), now representing 7% (11/165) of 
all NCDs. CONCLUSIONS: CMS’s NCD process is evolving in important ways. CMS 
increasingly notes that technologies considered lack relevant outcomes. The 
agency increasingly uses CED policies to grant narrow access to medical 
technology, while collecting evidence for future use. It increasingly uses NCDs to 
evaluate preventive services and diagnostic technologies.  
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